Is IMDX or ESLA more profitable?

Estrella Immunopharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Estrella Immunopharma N/A N/A -397.36%

Which has stronger earnings and valuation, OKUR or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is OKUR or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Estrella Immunopharma N/A N/A -397.36%

Which has stronger valuation and earnings, ESLA or IPHA?

Estrella Immunopharma has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Innate Pharma $10.19M 17.51 -$55.64M N/A N/A

Is ESLA or IPHA more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Innate Pharma N/A N/A N/A

Estrella Immunopharma (ESLA) Competitors

$0.98 -0.02 (-2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.41%)

As of 04:10 PM Eastern

Compare

ESLA vs. IMDX, OKUR, ALEC, DERM, and IPHA

Should you buy Estrella Immunopharma stock or one of its competitors? MarketBeat compares Estrella Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Estrella Immunopharma include Oncocyte (IMDX), OnKure Therapeutics (OKUR), Alector (ALEC), Journey Medical (DERM), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.

How does Estrella Immunopharma compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Oncocyte had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 1 mentions for Oncocyte and 0 mentions for Estrella Immunopharma. Oncocyte's average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Oncocyte	Neutral
Estrella Immunopharma	Neutral

Oncocyte has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Estrella Immunopharma has lower revenue, but higher earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	42.89	-$50.22M	-$1.48	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 123.05%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 716.33%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Estrella Immunopharma	N/A	N/A	-397.36%

Summary

Estrella Immunopharma beats Oncocyte on 6 of the 11 factors compared between the two stocks.

How does Estrella Immunopharma compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Estrella Immunopharma's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Estrella Immunopharma	N/A	N/A	-397.36%

In the previous week, OnKure Therapeutics had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for OnKure Therapeutics and 0 mentions for Estrella Immunopharma. OnKure Therapeutics' average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
OnKure Therapeutics	Neutral
Estrella Immunopharma	Neutral

OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

OnKure Therapeutics currently has a consensus target price of $27.00, suggesting a potential upside of 522.12%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 716.33%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Estrella Immunopharma beats OnKure Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Estrella Immunopharma compare to Alector?

Alector (NASDAQ:ALEC) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

85.8% of Alector shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Estrella Immunopharma has lower revenue, but higher earnings than Alector. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.44	-$142.93M	-$1.19	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Alector presently has a consensus price target of $3.63, indicating a potential upside of 102.51%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 716.33%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma has a net margin of 0.00% compared to Alector's net margin of -680.83%. Estrella Immunopharma's return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Estrella Immunopharma	N/A	N/A	-397.36%

In the previous week, Alector had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for Alector and 0 mentions for Estrella Immunopharma. Alector's average media sentiment score of 0.54 beat Estrella Immunopharma's score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Overall Sentiment
Alector	Positive
Estrella Immunopharma	Neutral

Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Alector beats Estrella Immunopharma on 9 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 89.78%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 716.33%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Journey Medical has higher revenue and earnings than Estrella Immunopharma. Journey Medical is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	3.05	-$11.43M	-$0.37	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Estrella Immunopharma has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Estrella Immunopharma's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Estrella Immunopharma	N/A	N/A	-397.36%

In the previous week, Journey Medical's average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Journey Medical	Neutral
Estrella Immunopharma	Neutral

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Journey Medical beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Innate Pharma?

Estrella Immunopharma (NASDAQ:ESLA) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Innate Pharma	N/A	N/A	N/A

In the previous week, Estrella Immunopharma's average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
Innate Pharma	Neutral

Estrella Immunopharma has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Innate Pharma	$10.19M	17.51	-$55.64M	N/A	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 716.33%. Innate Pharma has a consensus target price of $5.00, suggesting a potential upside of 163.16%. Given Estrella Immunopharma's higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Innate Pharma beats Estrella Immunopharma on 5 of the 9 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.03M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-2.88	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-3.63	8.26	10.76	6.41
Net Income	-$13.06M	$23.91M	$3.56B	$337.14M
7 Day Performance	-2.97%	3.05%	1.37%	-0.48%
1 Month Performance	-15.52%	2.40%	0.81%	0.49%
1 Year Performance	2.08%	56.35%	30.53%	28.16%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	2.7106 of 5 stars	$0.98 -2.0%	$8.00 +716.3%	+8.7%	$43.03M	N/A	N/A	N/A
IMDX Oncocyte	1.9254 of 5 stars	$5.32 flat	$12.00 +125.6%	N/A	$171.78M	$4.05M	N/A	120
OKUR OnKure Therapeutics	2.1212 of 5 stars	$4.29 +0.9%	$27.00 +529.4%	+74.3%	$171.68M	N/A	N/A	N/A
ALEC Alector	2.8008 of 5 stars	$1.56 +1.3%	$3.63 +132.4%	+33.1%	$170.98M	$21.05M	N/A	270	News Coverage Positive News
DERM Journey Medical	2.0138 of 5 stars	$5.92 -3.1%	$13.00 +119.6%	+5.0%	$168.24M	$61.86M	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. IMDX, OKUR, ALEC, DERM, and IPHA

How does Estrella Immunopharma compare to Oncocyte?

Summary

How does Estrella Immunopharma compare to OnKure Therapeutics?

Summary

How does Estrella Immunopharma compare to Alector?

Summary

How does Estrella Immunopharma compare to Journey Medical?

Summary

How does Estrella Immunopharma compare to Innate Pharma?

Summary

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. IMDX, OKUR, ALEC, DERM, and IPHA

How does Estrella Immunopharma compare to Oncocyte?

Does the media refer more to IMDX or ESLA?

Which has more volatility & risk, IMDX or ESLA?

Which has preferable valuation and earnings, IMDX or ESLA?

Do institutionals and insiders believe in IMDX or ESLA?

Do analysts rate IMDX or ESLA?

Is IMDX or ESLA more profitable?

Summary

How does Estrella Immunopharma compare to OnKure Therapeutics?

Do institutionals & insiders believe in OKUR or ESLA?

Is OKUR or ESLA more profitable?

Does the media refer more to OKUR or ESLA?

Which has more volatility & risk, OKUR or ESLA?

Which has stronger earnings and valuation, OKUR or ESLA?

Do analysts prefer OKUR or ESLA?

Summary

How does Estrella Immunopharma compare to Alector?

Do insiders & institutionals believe in ALEC or ESLA?

Which has better valuation and earnings, ALEC or ESLA?

Do analysts prefer ALEC or ESLA?

Is ALEC or ESLA more profitable?

Does the media refer more to ALEC or ESLA?

Which has more risk and volatility, ALEC or ESLA?

Summary

How does Estrella Immunopharma compare to Journey Medical?

Do insiders & institutionals believe in DERM or ESLA?

Do analysts prefer DERM or ESLA?

Which has better valuation and earnings, DERM or ESLA?

Is DERM or ESLA more profitable?

Does the media refer more to DERM or ESLA?

Which has more risk and volatility, DERM or ESLA?

Summary

How does Estrella Immunopharma compare to Innate Pharma?

Is ESLA or IPHA more profitable?

Does the media favor ESLA or IPHA?

Which has stronger valuation and earnings, ESLA or IPHA?

Do insiders and institutionals hold more shares of ESLA or IPHA?

Which has more risk & volatility, ESLA or IPHA?

Do analysts prefer ESLA or IPHA?

Summary

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools